Skip to content

Effect of Chandraprabha Vati along with Gokshuradi Guggulu in patients of Benign Prostatic Hyperplasia (BPH)

Evaluation of the efficacy & safety of ChandraprabhaVati with Gokshuradi Guggulu in the management of benign prostatic hyperplasia- A randomized, standard controlled clinical trial

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/06/053971
Enrollment
70
Registered
2023-06-16
Start date
Unknown
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N40- Benign prostatic hyperplasia

Interventions

None listed

Sponsors

Central Council for Research in Ayurvedic Sciences, Ministry of AYUSH, Goverment of India
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Prostate volume > 20 and = 50 gm by Transabdominal ultrasound 2. Newly diagnosed case of BPH or who have discontinued any other medication for BPH or related complaints for minimum three months prior to enrollment 3. Willing and able to give written informed consent and comply with study procedures 4. Willing and able to participate in the study for full three months.

Exclusion criteria

Exclusion criteria: 1. PSA > 4 ng/ml 2. Previous prostatic surgery (including TURP, balloon dilatation, thermotherapy, and stent replacement) or other invasive procedures to treat BPH 3. Post-void residual volume >250mL (Transabdominal ultrasound) 4. history of Acute Urine Retention within three months before screening 5. History of confirmed malignancy or cancer of prostate or bladder or has an imminent need for surgery 6. Participants with uncontrolled Hypertension with or without medication. (BP= 160/100 mm of Hg) 7. Participants with uncontrolled Diabetes mellitus with or without medication (HbA1c > 8%). 8. Participants with concurrent serious cardiac dysfunction or Hepatic Dysfunction (defined as AST and/or ALT >two times of the standard upper limit) or Renal Dysfunction as serum creatinine level more than the upper limit of lab value, uncontrolled Pulmonary Dysfunction (Asthmatic and COPD patients) or any other concurrent severe disease. 9. Participants participating in any other clinical study or having participated in any other study 1 month prior to screening in the present study 10. Participants who are taking Ayurvedic treatment/medicine for any disease condition for the last three months 11. Participants with impaired cognition, or with a history or diagnosis of psychiatric illness and neurological disorders, etc 12. Subjects who are already taking any other medication for treatment of BPH or any related complaints 13. Use of Any other condition that PI may think can jeopardize the study.

Design outcomes

Primary

MeasureTime frame
•Changes in Lower Urinary Tract Symptoms (LUTS) & quality of life in men with benign prostatic hyperplasia by International Prostate Symptom Score (IPSS) •Changes in prostate volume, post-void residual (PVR), Maximum flow rate, Mean flow rate Timepoint: 03 Months

Secondary

MeasureTime frame
•Changes in laboratory parameter viz. CBC, LFT, RFT & Lipid profileTimepoint: 03 Months

Countries

India

Contacts

Public ContactDr Aaditya Bhavanbhai Shah

Regional Ayurveda Research Institute, (Central Council for Research in Ayurvedic Sciences) Jammu

dr.aaditya.shah@gov.in9033236720

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026